Rexahn Adds Drug Conjugate Platform To Its Oncology Offerings
This article was originally published in The Pink Sheet Daily
Executive Summary
The Rockville, Md.-based biotech hopes to bring more value to shareholders through a slew of polymer-conjugated cancer drugs that it will add to its pipeline while it continues moving its three lead cancer compounds forward.